Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLA 1601

Next Previous
Drug Profile

VLA 1601

Alternative Names: VLA-1601; Zika virus vaccine - Emergent BioSolutions/Valneva; ZIKV-VLA1601

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valneva
  • Developer Emergent BioSolutions; Valneva
  • Class Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 25 Mar 2024 Phase-I clinical trials in Zika virus infection (In adults, Prevention) in USA (IM) (NCT06334393)
  • 28 Mar 2023 VLA 1601 is still in phase-I trials for Zika virus infections (prevention) in USA (Valneva pipeline, March 2023)
  • 28 Mar 2021 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention, In volunteers) in USA (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top